Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy

International Journal of Dermatology

Volumn 43, Issue 9, 2004, Pages 682-684

  Cunha, Paulo Rowilson ^a,b,c,d   de Oliveira, Josenildo Rodrigues ^a,b,c   Salles, Maria José ^a,b,c   Jamora, Jasmin ^a,b,c   Bystryn, Jean Claude ^a,b,c  

^a FACULDADE DE MEDICINA DE JUNDIAÍ   (Brazil)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELL ANTIBODY; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN G; NICOTINAMIDE; PREDNISONE; STEROID; TETRACYCLINE; THALIDOMIDE;

ACANTHOLYSIS; ADULT; ANTIBODY TITER; ARTICLE; BLISTER; CASE REPORT; CAUCASIAN; COMPLEMENT DEPOSITION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DYSPHAGIA; FEMALE; GINGIVA DISEASE; HIGH OUTPUT HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; LEG MUSCLE; MOUTH ULCER; MUSCLE WEAKNESS; ORAL BIOPSY; OUTCOMES RESEARCH; PALATE; PARESTHESIA; PEMPHIGUS VULGARIS; REMISSION; TONGUE DISEASE; UTERINE CERVIX DISEASE;

AZATHIOPRINE; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PEMPHIGUS; PREDNISONE; THALIDOMIDE; UTERINE CERVICAL DISEASES;

EID: 4644288041     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02174.x     Document Type: Article

References (12)

1. Bystryn JC. Therapy of pemphigus. Seminars Dermatol 1988; 7: 186-194.
2. D'Arcy PF, Griffin JP. Thalidomide revisited. Adverse Drug React Toxicol Ver 1994; 13: 65-76.
3. McBride W. Thalidomide embryopathy. Teratology 1997; 16: 79-82.
4. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
5. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303.
6. Calderon P, Anzilotti M, Philips R. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997; 36: 881-887.
7. Tseng SBA, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanisms of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-979.
8. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980; 269: 175-280.
9. Barnhill RL, Doll NJ, Millikan LE, et al. Studies on the anti-inflamatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814-819.
10. Ching LM, Xu ZF, Gummer BH, et al. Effect of thalidomide on tumor necrosis factor production and antitumor activity induced by 5,6-dimethyl-xanthenone-4-acetic acid. Br J Cancer 1995; 72: 339-343.
11. Sampio EP, Kaplan G, Miranda A. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-414.
12. Ochoniskv S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 73-76.